SHR-3821 / Jiangsu Hengrui Pharma - LARVOL DELTA

A phase 1 study of SHR-3821, an ADCC-enhanced CLDN18.2/4-1BB bispecific antibody, in patients with advanced solid tumors (ESMO 2026) - No abstract available

ADC • Bispecific • Clinical • Metastases • P1 data • Oncology • Solid Tumor • CLDN18

A phase 1 study of SHR-3821, an ADCC-enhanced CLDN18.2/4-1BB bispecific antibody, in patients with advanced solid tumors. (ASCO 2026) - P1 | "SHR-3821 showed tolerable safety and promising antitumor activity in patients with CLDN18.2-positive GC and PC. These data support further clinical development of SHR-3821. Efficacy in GC and PC."

ADC • Bispecific • Clinical • Metastases • P1 data • Gastric Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CLDN18

SHR-3821 in Advanced Colorectal Cancer: an Exploratory Study (clinicaltrials.gov) - P2 | N=12 | Not yet recruiting | Sponsor: Meng Qiu

New P2 trial • Colorectal Cancer • Oncology • Solid Tumor • MSI

SHR-3821-101: A Study of SHR-3821 Injection in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=162 | Recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

A Study of SHR-3821 Injection in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=162 | Not yet recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

New P1 trial • Oncology • Solid Tumor

Hengrui Medicine: Clinical trials of its subsidiary drugs SHR-3821 injection and SHR-7787 injection were approved [Google translation] (163.com) - "On August 9, Hengrui Medicine (600276) issued an announcement...that its subsidiaries Shanghai Shengdi Pharmaceutical Co., Ltd., Shanghai Hengrui Medicine Co., Ltd. and Suzhou Shengdia Biopharmaceutical Co., Ltd. received the 'Drug Clinical Trial Approval Notice' for SHR-3821 Injection and SHR-7787 Injection approved by the National Medical Products Administration, and clinical trials will be carried out in the near future. SHR-3821 injection is a humanized antibody drug independently developed by the company. It is intended to be used to treat advanced malignant solid tumors...SHR-7787 injection is a Class 1 therapeutic biological product that induces and activates T cells to enable them to play a role in targeted killing of malignant solid tumor cells."

New trial • Hematological Malignancies • Oncology • Solid Tumor